GSK872 Inhibits RIPK3 Kinase Activity to Suppress Acidification-Induced Synovial Invasion in Arthritis

Schematic diagram of ASIC1a RIPK3 MDH1 signaling pathway showing metabolic inhibition in synoviocytes
Feel free to reference this image, but please provide a link back.
Copy code to add this image to your page

Microenvironmental acidification in the synovial joint space of rheumatoid arthritis (RA) creates an acidic niche, dropping extracellular pH to approximately 6.8. This localized acidosis acts as a potent signaling stimulus for resident fibroblast-like synoviocytes (RA-FLS). Acid-sensing ion channel 1a (ASIC1a), a proton-gated cation channel highly expressed on synoviocytes, senses this pH decline and initiates an intracellular signaling cascade. Rather than inducing classical ion channel-mediated membrane depolarizations alone, ASIC1a engagement physically recruits receptor-interacting serine/threonine-protein kinase 3 (RIPK3).

Classically, RIPK3 is recognized as an essential component of the necroptotic cell death pathway downstream of TNF receptor activation and RIPK1 interaction. However, under non-lethal microenvironmental stress such as mild extracellular acidosis, RIPK3 executes non-necroptotic enzymatic functions. Phosphorylation of RIPK3 occurs directly upon interaction with activated ASIC1a without requiring MLKL phosphorylation or assembly of the canonical necrosome complex. Phosphorylated RIPK3 functions as a metabolic switch rather than an executioner of cell death.

Downstream of ASIC1a engagement, phosphorylated RIPK3 physically associates with malate dehydrogenase 1 (MDH1), a cytosolic enzyme integral to the malate-aspartate shuttle. This protein-protein interaction stimulates MDH1 catalytic activity, accelerating the transfer of reducing equivalents from cytosolic NADH into the mitochondrial matrix. Consequently, mitochondrial electron transport chain activity accelerates, driving oxidative phosphorylation and elevating intracellular adenosine triphosphate (ATP) production.

In parallel with MDH1 activation, the ASIC1a-RIPK3 axis enhances glutaminase 1 (GLS1) expression and glutaminolysis, while upregulating aerobic glucose metabolism. This coordinated metabolic shift supplies carbon intermediates and energy necessary to sustain structural and phenotypic transformations in RA-FLS. Elevated mitochondrial respiration directly supports the transcriptional upregulation and membrane translocation of N-cadherin, alongside increased expression and secretion of matrix metalloproteinase 3 (MMP3). These molecular effectors facilitate extracellular matrix degradation and cell-matrix turnover, promoting synoviocyte migration and invasive growth into periarticular cartilage and bone.

The small molecule compound GSK872 functions as a selective kinase inhibitor of RIPK3. By binding the ATP-binding pocket of RIPK3, GSK872 abolishes its catalytic kinase activity. In the context of acid-stimulated synoviocytes, GSK872 prevents RIPK3 phosphorylation without inducing apoptosis or systemic cytotoxicity. Systematic evaluation through small molecule kinase inhibitor profiling demonstrates that GSK872 specifically decouples the ASIC1a-RIPK3-MDH1 signaling axis.

Treatment of primary RA-FLS with GSK872 suppresses acidification-induced MDH1 activation and attenuates malate-aspartate shuttle activity. This enzymatic blockade decreases mitochondrial oxygen consumption rates (OCR) and diminishes cellular ATP pools. Lacking the metabolic output required for cellular remodeling, RA-FLS exhibit reduced MMP3 secretion and N-cadherin downregulation. Consequently, in vitro transwell migration and Matrigel invasion assays demonstrate significant reductions in synoviocyte motility following GSK872 exposure.

The therapeutic relevance of targeting RIPK3 via GSK872 extends to in vivo preclinical models of autoimmune arthritis. In murine collagen-induced arthritis (CIA), systemic administration of GSK872 reduces paw swelling, clinical arthritis scores, and synovial hyperplasia. Histological evaluation reveals marked reduction in pan-synovial inflammatory cell infiltration, reduced cartilage erosion, and protected subchondral bone structures. Importantly, the suppression of disease severity in CIA mice occurs independently of necroptosis inhibition, confirming that RIPK3-driven metabolic reprogramming in synoviocytes represents an actionable target in inflammatory joint disease.


Pharmacological Blockade of Synovial Metabolic Reprogramming

GSK872 regulation of ASIC1a RIPK3 MDH1 signaling pathway showing metabolic inhibition in synoviocytes
Feel free to reference this image, but please provide a link back.
Copy code to add this image to your page

GSK872 selectively inhibits RIPK3 kinase activity, decoupling the ASIC1a-RIPK3 interaction induced by microenvironmental acidification (pH 6.8). This blockade prevents downstream MDH1 activation, halting malate-aspartate shuttle flux, aerobic glycolysis, and GLS1-dependent glutaminolysis in synoviocytes. By dampening mitochondrial respiration and ATP generation, GSK872 downregulates N-cadherin and MMP3, suppressing RA-FLS invasion and joint erosion in preclinical arthritis models.

ASIC1a-Driven RIPK3 Activation Reprograms Synoviocyte Respiration

Extracellular acidification triggers metabolic adaptation in rheumatoid arthritis fibroblast-like synoviocytes (RA-FLS). At a localized pH of 6.8, acid-sensing ion channel 1a (ASIC1a) physically recruits RIPK3. This recruitment stimulates RIPK3 phosphorylation without inducing necroptotic cell death. Phosphorylated RIPK3 binds malate dehydrogenase 1 (MDH1); this complex enhances malate-aspartate shuttle flux to sustain mitochondrial oxidative phosphorylation. Concurrently, glutaminase 1 (GLS1) activity increases, fueling glutaminolysis and aerobic glucose turnover. High ATP yields supply the energy required for structural remodeling. Application of GSK872 disrupts this signaling cascade at nanomolar concentrations. Pharmacological target engagement attenuates downstream MDH1 phosphorylation; mitochondrial oxygen consumption rates decrease rapidly as a result. Cellular ATP levels drop sharply following target engagement. In cultured primary synoviocytes, this metabolic deprivation correlates with reduced expression of matrix metalloproteinase 3 (MMP3) and N-cadherin.

GSK872 Attenuates Synovial Invasion and Joint Destruction in Vivo

Targeting RIPK3 alters synoviocyte behavior in structural assay systems. In transwell migration and Matrigel invasion assays, GSK872 suppressed RA-FLS motility under acidic culture conditions. Cell migration distances decreased significantly. In murine collagen-induced arthritis (CIA) models, systemic administration of GSK872 reduced clinical disease indices and hind paw swelling. Histological analysis revealed diminished inflammatory cell infiltration into the synovial space; cartilage degradation and periarticular bone erosion were substantially attenuated within treated animals. Osteoclast numbers along the bone-pannus interface declined markedly. Notably, systemic necroptosis markers remained unchanged in treated tissue samples. These empirical observations confirm that the therapeutic efficacy of GSK872 stems from blocking metabolic signaling cascades rather than inducing systemic cytotoxicity.


References

[1]. Hu W, et al. Theranostics. 2025;15(17):8719-8737.

Resources